Trial Profile

A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Efficacy Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone or in Combination With Durvalumab for Patients With Advanced Malignancies

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; MRNA-2416 (Primary)
Indications Carcinoma; Fallopian tube cancer; Lymphoma; Ovarian cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Moderna Therapeutics

04 Jun 2025 Results assessing the safety, tolerability, and efficacy of mRNA-2416 alone (arm A) or with durvalumab (arm B) in patients with advanced solid tumors or lymphoma were published in the Oncologist.
07 Jul 2022 Status changed from active, no longer recruiting to discontinued.
12 Aug 2021 Planned End Date changed from 22 Mar 2023 to 20 Sep 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com